|
GB9716101D0
(en)
|
1997-07-30 |
1997-10-01 |
Pharmacia & Upjohn Spa |
Fused heterocyclic compounds
|
|
US5914405A
(en)
|
1997-10-07 |
1999-06-22 |
Eli Lilly And Company |
Process for preparing 3-substituted indazoles
|
|
GB9911053D0
(en)
|
1999-05-12 |
1999-07-14 |
Pharmacia & Upjohn Spa |
4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
|
|
JP2004508359A
(ja)
|
2000-09-06 |
2004-03-18 |
ニューロゲン コーポレイション |
アリール置換テトラヒドロインダゾール、及び、ｇａｂａ−ａ受容体に対するリガンドとしてのそれらの使用
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
JP2012506848A
(ja)
|
2008-10-27 |
2012-03-22 |
グラクソ グループ リミテッド |
グルタミン酸受容体モジュレーターとしての三環式化合物
|
|
EP2202232A1
(en)
|
2008-12-26 |
2010-06-30 |
Laboratorios Almirall, S.A. |
1,2,4-oxadiazole derivatives and their therapeutic use
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
WO2012087782A1
(en)
|
2010-12-23 |
2012-06-28 |
Boehringer Ingelheim International Gmbh |
Pyrazolopiperidine compounds as ccr1 receptor antagonists
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2015188369A1
(en)
|
2014-06-13 |
2015-12-17 |
Merck Sharp & Dohme Corp. |
Purine inhibitors of human phosphatidylinositol 3-kinase delta
|
|
WO2016109684A2
(en)
|
2014-12-30 |
2016-07-07 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis b infections
|
|
WO2016144825A1
(en)
|
2015-03-11 |
2016-09-15 |
Peloton Therapeutics, Inc. |
Aromatic compounds and uses thereof
|
|
WO2017120508A1
(en)
|
2016-01-08 |
2017-07-13 |
Arcus Biosciences, Inc. |
Modulators of 5'-nucleotidase, ecto and the use thereof
|
|
EP3518934A4
(en)
|
2016-10-03 |
2020-06-24 |
Arcus Biosciences, Inc. |
Inhibitors of adenosine 5'-nucleotidase
|
|
WO2018094148A1
(en)
|
2016-11-18 |
2018-05-24 |
Arcus Biosciences, Inc. |
Inhibitors of cd73-mediated immunosuppression
|
|
HUE064141T2
(hu)
|
2017-01-20 |
2024-02-28 |
Arcus Biosciences Inc |
Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
|
|
ES2953349T3
(es)
|
2017-05-05 |
2023-11-10 |
Arcus Biosciences Inc |
Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
|
|
PL3634417T3
(pl)
|
2017-05-17 |
2023-09-25 |
Arcus Biosciences, Inc. |
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
|
|
AU2019229978B2
(en)
|
2018-03-05 |
2024-05-30 |
Arcus Biosciences, Inc. |
Arginase inhibitors
|
|
PL3829581T3
(pl)
|
2018-07-27 |
2024-07-01 |
Arcus Biosciences, Inc. |
Antagoniści pirydonu a2r
|
|
WO2020046813A1
(en)
|
2018-08-27 |
2020-03-05 |
Arcus Biosciences, Inc. |
Cd73 inhibitors
|
|
TWI828800B
(zh)
|
2018-11-16 |
2024-01-11 |
美商阿克思生物科學有限公司 |
Arg1及/或arg2之抑制劑
|
|
CN114206332B
(zh)
|
2019-06-04 |
2024-08-23 |
艾库斯生物科学有限公司 |
2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
|
|
AU2020312800B2
(en)
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
|
|
CN119118872A
(zh)
*
|
2020-03-19 |
2024-12-13 |
艾库斯生物科学有限公司 |
作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
|
|
MX2022015157A
(es)
|
2020-06-02 |
2023-01-16 |
Arcus Biosciences Inc |
Anticuerpos para tigit.
|
|
CA3186769A1
(en)
*
|
2020-06-11 |
2021-12-16 |
Betta Pharmaceuticals Co., Ltd |
Bicyclic compounds and use thereof
|
|
WO2022063115A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
贝达药业股份有限公司 |
双环化合物及其应用
|